Research programme: fetal growth retardation gene therapy - Magnus Life Science

Drug Profile

Research programme: fetal growth retardation gene therapy - Magnus Life Science

Alternative Names: Fetal growth retardation gene therapy - Magnus Growth

Latest Information Update: 20 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Magnus Life Science; University College London
  • Class Gene therapies
  • Mechanism of Action Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Fetal growth retardation

Most Recent Events

  • 08 Jan 2015 European Medicines Agency (EMA)'s Committee for Orphan Medicinal Products (COMP) recommends orphan drug designation for gene therapy in European Union for Fetal growth retardation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top